Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.

Schizophrenia (SCZ) has been associated with serotonergic and endocannabinoid systems dysregulation, but difficulty in obtaining in vivo neurological tissue has limited its exploration. We investigated CB1R-5-HT2AR heteromer expression and functionality via intracellular pERK and cAMP quantification in olfactory neuroepithelium (ON) cells of SCZ patients non-cannabis users (SCZ/nc), and evaluated whether cannabis modulated these parameters in patients using cannabis (SCZ/c). Results were compared vs healthy controls non-cannabis users (HC/nc) and healthy controls cannabis users (HC/c). Further, antipsychotic effects on heteromer signaling were tested in vitro in HC/nc and HC/c. Results indicated that heteromer expression was enhanced in both SCZ groups vs HC/nc. Additionally, pooling all 4 groups together, heteromer expression correlated with worse attentional performance and more neurological soft signs (NSS), indicating that these changes may be useful markers for neurocognitive impairment. Remarkably, the previously reported signaling properties of CB1R-5-HT2AR heteromers in ON cells were absent, specifically in SCZ/nc treated with clozapine. These findings were mimicked in cells from HC/nc exposed to clozapine, suggesting a major role of this antipsychotic in altering the quaternary structure of the CB1R-5-HT2AR heteromer in SCZ/nc patients. In contrast, cells from SCZ/c showed enhanced heteromer functionality similar to HC/c. Our data highlight a molecular marker of the interaction between antipsychotic medication and cannabis use in SCZ with relevance for future studies evaluating its association with specific neuropsychiatric alterations.

[1]  L. Pardo,et al.  Control of glutamate release by complexes of adenosine and cannabinoid receptors , 2020, BMC Biology.

[2]  Sarah L. Withey,et al.  Δ-Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons , 2019, iScience.

[3]  Andrea Cipriani,et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis , 2019, The Lancet.

[4]  Eduard Bentea,et al.  Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. , 2019, Molecular omics.

[5]  E. Vieta,et al.  Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis , 2019, European Neuropsychopharmacology.

[6]  R. Murray,et al.  High-potency cannabis and incident psychosis: correcting the causal assumption - Authors' reply. , 2019, Lancet psychiatry.

[7]  S. Iwata,et al.  Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.

[8]  S. Iwata,et al.  Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.

[9]  I. Ibarra-Lecue,et al.  Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway , 2018, Neuropsychopharmacology.

[10]  G. Benítez-King,et al.  Exfoliated Human Olfactory Neuroepithelium: A Source of Neural Progenitor Cells , 2018, Molecular Neurobiology.

[11]  P. Robledo,et al.  Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells , 2018, Molecular Neurobiology.

[12]  J. Kane,et al.  Improving outcomes of first‐episode psychosis: an overview , 2017, World psychiatry : official journal of the World Psychiatric Association.

[13]  C. Trueta,et al.  The role of melatonin in the neurodevelopmental etiology of schizophrenia: A study in human olfactory neuronal precursors , 2017, Journal of pineal research.

[14]  Jarek Meller,et al.  Abnormalities of signal transduction networks in chronic schizophrenia , 2017, npj Schizophrenia.

[15]  Yongchao Ge,et al.  Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects , 2017, Nature Neuroscience.

[16]  Shan Jiang,et al.  Crystal structures of agonist-bound human cannabinoid receptor CB1 , 2017, Nature.

[17]  M. García-Anaya,et al.  Human neural stem/progenitor cells derived from the olfactory epithelium express the TrkB receptor and migrate in response to BDNF , 2017, Neuroscience.

[18]  A. Sawa,et al.  Application of olfactory tissue and its neural progenitors to schizophrenia and psychiatric research , 2017, Current opinion in psychiatry.

[19]  M. Parellada,et al.  Cannabis use, COMT, BDNF and age at first-episode psychosis , 2017, Psychiatry Research.

[20]  M. Clarke,et al.  Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode , 2017, BMJ Open.

[21]  Peter B. Jones,et al.  Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort , 2017, Psychiatry Research.

[22]  Robin M. Murray,et al.  The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia , 2017, Biological Psychiatry.

[23]  C. Trueta,et al.  The microtubular cytoskeleton of olfactory neurons derived from patients with schizophrenia or with bipolar disorder: Implications for biomarker characterization, neuronal physiology and pharmacological screening , 2016, Molecular and Cellular Neuroscience.

[24]  S. Łukasiewicz,et al.  Dopamine D2 and serotonin 5‐HT1A receptor interaction in the context of the effects of antipsychotics – in vitro studies , 2016, Journal of neurochemistry.

[25]  J. C. Morales-Medina,et al.  Neuronal and brain morphological changes in animal models of schizophrenia , 2016, Behavioural Brain Research.

[26]  C. Chiou,et al.  Global economic burden of schizophrenia: a systematic review , 2016, Neuropsychiatric disease and treatment.

[27]  M. Packard,et al.  The influence of cannabinoids on learning and memory processes of the dorsal striatum , 2015, Neurobiology of Learning and Memory.

[28]  V. Pérez,et al.  Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study. , 2015, Psychiatric services.

[29]  P. Robledo,et al.  Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors , 2015, PLoS biology.

[30]  Karin E. Borgmann-Winter,et al.  Translational potential of olfactory mucosa for the study of neuropsychiatric illness , 2015, Translational Psychiatry.

[31]  E. Velthorst,et al.  Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study , 2015, Psychological Medicine.

[32]  R. Keefe The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. , 2014, The Journal of clinical psychiatry.

[33]  A. Bachoud-Lévi,et al.  Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis , 2014, European Journal of Clinical Pharmacology.

[34]  E P Noble,et al.  Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients , 2014, Translational Psychiatry.

[35]  H. Okano,et al.  Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: Utility and limitation of the surrogate tissues in research for brain disorders , 2013, Neuroscience Research.

[36]  J. González-Maeso,et al.  Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects , 2013, European Neuropsychopharmacology.

[37]  A. Mackay-Sim Concise Review: Patient‐Derived Olfactory Stem Cells: New Models for Brain Diseases , 2012, Stem cells.

[38]  Robert B. Innis,et al.  Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia , 2012, Schizophrenia Research.

[39]  M. Ferrín,et al.  Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. , 2012, Current pharmaceutical design.

[40]  John M. Davis,et al.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis , 2012, The Lancet.

[41]  D. Kelly,et al.  The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .

[42]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[43]  Deanna M. Barch,et al.  Cognition in schizophrenia: core psychological and neural mechanisms , 2012, Trends in Cognitive Sciences.

[44]  G. Benítez-King,et al.  A non-invasive method to isolate the neuronal linage from the nasal epithelium from schizophrenic and bipolar diseases , 2011, Journal of Neuroscience Methods.

[45]  Jessica A. Turner,et al.  Identifying gene regulatory networks in schizophrenia , 2010, NeuroImage.

[46]  C. Wells,et al.  Disease-specific, neurosphere-derived cells as models for brain disorders , 2010, Disease Models & Mechanisms.

[47]  W. Koltun,et al.  Primary cell lines: false representation or model system? a comparison of four human colorectal tumors and their coordinately established cell lines. , 2010, International journal of clinical and experimental medicine.

[48]  J. Kleinman,et al.  Epigenetic mechanisms in schizophrenia. , 2009, Biochimica et biophysica acta.

[49]  S. Faraone,et al.  Neurocognition in first-episode schizophrenia: a meta-analytic review. , 2009, Neuropsychology.

[50]  J. Fernández-Ruiz The endocannabinoid system as a target for the treatment of motor dysfunction , 2009, British journal of pharmacology.

[51]  G. Kinsella,et al.  Effect of age on forward and backward span tasks , 2004, Journal of the International Neuropsychological Society.

[52]  J. Sweatt,et al.  Mitogen-activated protein kinases in synaptic plasticity and memory , 2004, Current Opinion in Neurobiology.

[53]  Therese Garrick,et al.  Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[54]  Jeffrey A Lieberman,et al.  Recent advances in the neurobiology of schizophrenia. , 2003, Molecular interventions.

[55]  Robin M. Murray,et al.  Neurological soft signs in first-episode psychosis: A systematic review , 2002, British Journal of Psychiatry.

[56]  N. Darmani Cannabinoids of diverse structure inhibit two DOI-induced 5-HT2A receptor-mediated behaviors in mice , 2001, Pharmacology Biochemistry and Behavior.

[57]  A. Baddeley,et al.  The Quarterly Journal of Experimental Psychology Section a Human Experimental Psychology Dementia and Working Memory Dementia and Working Memory , 2022 .

[58]  D. Moran,et al.  The fine structure of the olfactory mucosa in man , 1982, Journal of neurocytology.

[59]  Dan J Stein,et al.  Polygenic risk for schizophrenia and associated brain structural changes: A systematic review. , 2019, Comprehensive psychiatry.

[60]  Julie Kreyenbuhl,et al.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.

[61]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.